Lexicon Pharmaceuticals (LXRX) Total Non-Current Liabilities (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Total Non-Current Liabilities data on file, last reported at $59.6 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $59.6 million, down 64.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $59.6 million (down 64.81% YoY), and the FY2025 annual result was $70.3 million, down 51.72% from the prior year.
• Total Non-Current Liabilities retreated to $59.6 million in Q1 2026 per LXRX's latest filing, from $70.3 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $169.3 million in Q1 2025 and troughed at $40.5 million in Q2 2022.
• A 5-year average of $93.3 million and a median of $78.2 million in 2025 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2026: Total Non-Current Liabilities surged 224.31% in 2022, then plunged 64.81% in 2026.
• A 5-year view of Total Non-Current Liabilities shows it stood at $71.8 million in 2022, then jumped by 82.65% to $131.1 million in 2023, then advanced by 11.06% to $145.5 million in 2024, then plunged by 51.72% to $70.3 million in 2025, then declined by 15.22% to $59.6 million in 2026.
• Business Quant data shows LXRX's Total Non-Current Liabilities at $59.6 million in Q1 2026, $70.3 million in Q4 2025, and $78.2 million in Q3 2025.